Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMN-alloRIC: Lenalidomide and Bortezomib in RIC Allogeneic Transplantation
NCT01460420Phase 2Completed
- Start
- Nov 2011
- Primary completion
- Jun 2017
- Modality
- Small Molecules, Modified Peptides
- Countries
- 4
01
Overview
A Phase 2 trial of bortezomib, lenalidomide in hematologic malignancy, multiple myeloma (MM). Started Nov 2011; status: completed.
02
Drugs
bortezomiblenalidomide
03
Conditions
hematologic malignancymultiple myeloma (MM)
Beyond the preview
Go deeper on NCT01460420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01460420.